BioSpecifics Technologies is UNDERVALUED at 76.40 per share with modest projections ahead. BioSpecifics Technologies appears to be very steady, given 1 month investment horizon.
BioSpecifics Technologies secures Sharpe Ratio (or Efficiency) of 0.0771, which signifies that the company had 0.0771% of return per unit of risk over the last month. Our standpoint towards foreseeing the volatility of a stock is to use all available market data together with stock specific
technical indicators that cannot be
diversified away. We have found twenty-eight
technical indicators for BioSpecifics Technologies Corp, which you can use to evaluate future volatility of the firm. Please makes use of BioSpecifics Technologies Risk Adjusted Performance of 0.1481,
downside deviation of 2.6, and Mean Deviation of 2.11 to double-check if our risk estimates are consistent with your expectations.
How important is BioSpecifics Technologies's Liquidity
BioSpecifics Technologies
financial leverage refers to using borrowed capital as a funding source to finance BioSpecifics Technologies Corp ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. BioSpecifics Technologies financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to BioSpecifics Technologies' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of BioSpecifics Technologies' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between BioSpecifics Technologies's total debt and its cash.
Detailed Perspective On BioSpecifics Technologies
Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of BioSpecifics Technologies is not uncomon. There are few distinct groups of BioSpecifics Technologies stakehholders that the SEC considers insiders. Investors usually gain information through their work as corporate directors, officers, or employees. If these individuals share the information with a friend, family, or business partner and the person who receives the information exchanges stock in the company, he or shie is also an insider. Let's take a look at how the ownership of BioSpecifics is distributed among investors.
Ownership Allocation
The
market capitalization of BioSpecifics Technologies is $481.32 Million. Over half of BioSpecifics Technologies outstanding shares are owned by
other corporate entities. These other corporate entities are typically referred to corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these
institutions are subject to different rules and regulation than regular investors in BioSpecifics Technologies. Please watch out for any change in the
institutional holdings of BioSpecifics Technologies as this could mean something significant has changed or about to change at the company. Please take into account that even companies with profitable outlook can generate negative future returns on their equity. If the true value of the firm is less than the current market value, you may not be able generate positive returns on investment in the long run.
| Retail Investors7.11% | Insiders26.15% | Institutions66.74% |
| Retail Investors | 7.11 |
| Insiders | 26.15 |
| Institutions | 66.74 |
| 2019 | 2020 (projected) |
Interest Expense | 35.1 | 34.89 | Gross Profit | 38.19 M | 31.02 M |
Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. BioSpecifics Technologies has an asset utilization ratio of 86.94 percent. This suggests that the company is making $0.87 for each dollar of assets. An increasing asset utilization means that BioSpecifics Technologies Corp is more efficient with each dollar of assets it utilizes for everyday operations.
| Current Assets | 117.9 Million | 85.74 |
| Assets Non Current | 18.75 Million | 13.64 |
| Goodwill | 476,881 | 0.35 |
| Tax Assets | 370,329 | 0.27 |
Another 3 percent rise for BioSpecifics Technologies
Current variance is at 8.23. As of the 8th of August, BioSpecifics Technologies shows the Risk Adjusted Performance of 0.1481,
mean deviation of 2.11, and Downside Deviation of 2.6. BioSpecifics Technologies
technical analysis gives you the methodology to make use of
historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of
historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for nineteen
technical drivers for BioSpecifics Technologies Corp, which can be compared to its rivals. Please confirm
BioSpecifics Technologies jensen alpha, as well as the
relationship between the potential upside and
skewness to decide if BioSpecifics Technologies is priced correctly, providing market reflects its regular price of 65.53 per share. Given that BioSpecifics Technologies has
jensen alpha of 0.313, we suggest you to validate BioSpecifics Technologies Corp's prevailing market performance to make sure the company can sustain itself at a future point.
Our Final Perspective on BioSpecifics Technologies
Whereas some other companies under the biotechnology industry are still a bit expensive, BioSpecifics Technologies may offer a potential longer-term growth to investors. The inconsistency in the assessment between current BioSpecifics valuation and our trade advice on BioSpecifics Technologies is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to BioSpecifics Technologies.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of BioSpecifics Technologies Corp. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
